OPKO Health’s (OPK) “Outperform” Rating Reaffirmed at Barrington Research

Barrington Research reiterated their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a report published on Friday,Benzinga reports. Barrington Research currently has a $2.25 price objective on the biotechnology company’s stock.

OPK has been the subject of a number of other reports. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.74 on Friday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -9.16 and a beta of 1.63. The firm’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.55. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.84.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. As a group, sell-side analysts forecast that OPKO Health will post -0.25 earnings per share for the current year.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $1.56 per share, with a total value of $780,000.00. Following the acquisition, the chief executive officer now owns 212,411,477 shares in the company, valued at $331,361,904.12. This represents a 0.24 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 1,389,971 shares of company stock valued at $2,124,442 in the last ninety days. 47.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 8,064 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after buying an additional 8,396 shares during the last quarter. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the last quarter. Comerica Bank boosted its holdings in shares of OPKO Health by 18.2% in the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 16,369 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 18,571 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.